Ventilatory support in the intensive care unit

This article focuses on the functional features of positive-pressure ventilators, the modes of invasive and non-invasive mechanical ventilation, and the main ventilator settings. It also highlights the potential complications of mechanical ventilation, the basic principles of weaning, and the pathophysiological basis of patient-ventilator dyssynchrony.     

经鼻高流量氧气湿化治疗老年慢性阻塞性肺疾病急性加重合并呼吸衰竭的可行性研究

ObjectiveTo investigate the feasibility of transnasal heated humidified high flow nasal cannula oxygen therapy (HFNC) in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with respiratory failure in elderly patients. MethodsA total of 176 elderly patients with AECOPD complicated with respiratory failure who were hospitalized at Peking University Shougang Hospital from December 2016 to January 2022 were enrolled, including 82 patients in an HFNC group and 94 patients in an NPPV group. After treatment, pulse oxygen saturation (SPO₂), arterial partial pressure of carbon dioxide (PaCO₂), oxygenation index (OI), respiratory rate (RR), heart rate (HR), mean arterial pressure (MAP), comfort score, discharge rate, rate of endotracheal intubation, rate of transfer to intensive care unit (ICU), and mortality were compared between the two groups. The independent sample t-test was used for comparison between the two groups. Statistical data are expressed in percentage or number of cases and the χ² test was used for their comparisons. ResultsThe SPO₂ values at 30 min, 1 h, and 6 h were significantly higher in the HFNC group than in the NPPV group (t=-2.049,-2.618, and -3.314, P=0.043, 0.010, and 0.001, respectively). SPO₂ before discharge was significantly lower than that of the NPPV group (t=2.162, P=0.033), but OI at each time point and before discharge had no statistical significance (P＞0.05). MAP at 6 h was significantly higher in the HFNC group than in the NPPV group (t=-2.209, P=0.029), but within the normal range. HRs at 2 h and 3 h in the HFNC group were significantly higher than those of the NPPV group (t=-2.199 and -2.336, P=0.030 and 0.021, respectively). There were no significant differences in RR, HR, or MAP between the two groups at other time points and before discharge (P＞0.05). There was no significant difference in PaCO2 between the two groups (P＞0.05). Comfort score in the HFNC group was significantly higher than that of the NPPV group (t=-46.807, P＜0.001). There were no significant differences in discharge rate, ICU transfer rate, endotracheal intubation rate, and mortality between the two groups (P＞0.05). ConclusionHFNC is as effective as NPPV in treating elderly patients with AECOPD complicated with type Ⅰ or mild type Ⅱ respiratory failure, and HFNC is more comfortable than NPPV.     

Prevention of Descending Pneumonia in Rats with Perflubron-delivered Tobramycin

OBJECTIVES: Patients undergoing emergent endotracheal intubation are at increased risk for developing pneumonia. Although numerous strategies have been investigated to reduce ventilator-associated pneumonia (VAP), the incidence of VAP and its associated mortality remains high. This investigation tested the hypothesis that LiquiVent (Alliance Pharmaceutical, San Diego, CA-LV) delivered antibiotics (via spray-dried microspheres-SDM) would improve survival in a rat model of descending gram-negative pneumonia. METHODS: Wistar rats (n = 49) were randomized to receive prophylaxis with 1). nothing (controls); 2). intramuscular (IM) tobramycin, 3). intratracheal LV plus SDM shells (vehicle), 4). intratracheal LV plus SDM shells plus IM tobramycin, or 5). intratracheal LV plus SDM containing 1 mg/kg of tobramycin. All interventions were given 24 hours before a bacterial challenge with 10(8) colony-forming units of intratracheal Klebsiella pneumoniae. Mortality at ten days was the sole outcome measure. Survival in individual groups was compared with controls by Fisher's exact test with Bonferroni correction for multiple comparisons. RESULTS: All animals in the control group died of pneumonia within ten days of bacterial inoculation (0% survival). Prophylaxis with either IM tobramycin or SDM vehicle plus IM tobramycin provided no protection (0% survival). This is in sharp contrast to the cohort receiving pretreatment with tobramycin-containing SDM delivered via LV, in which 60% of the animals survived to study completion (p < 0.05). CONCLUSIONS: Prophylaxis with SDM containing antibiotics delivered in low-dose LV provided significant protection in a rat model of descending gram-negative pneumonia. These data support the hypothesis that perfluorocarbon-delivered intratracheal antimicrobials may be useful in the prevention of VAP.     

舒利迭加无创通气治疗稳定期慢性阻塞性肺疾病的临床研究

目的探讨舒利迭(吸入型肾上腺皮质激素与长效β2-受体激动剂的预混制剂)联合双水平气道正压通气(B iPAP)对稳定期慢性阻塞性肺疾病(COPD)的治疗作用。方法稳定期COPD病人52例,舒利迭TM50/250,1吸/次,2次/d;B iPAP,吸气压力(IPAP)10~20cm H2O,呼气压力(EPAP,也称PEEP)3~6cm H2O,吸氧浓度(FiO2)3L/m in,每天夜间通气6~8h。观察治疗前、治疗后12周病人临床症状、生活质量、健康状态和肺功能。结果治疗前、治疗后12周病人的临床症状、急性加重次数及严重程度、健康状态和生活质量、肺功能等指标比较差异有统计学意义(P<0.05)。结论舒利迭联合B iPAP治疗稳定期COPD病人能够明显改善其症状,提高生活质量,有一定的临床应用价值,对减缓COPD病人肺功能下降有积极意义。     

鸟牌呼吸机故障及排除三例

呼吸机在国内外医院广泛应用，详细介绍鸟牌呼吸机在临床上3例常见的故障和排除方法。     

长脉冲Nd:YAG激光非侵入性治疗皮肤浅表静脉畸形

目的前瞻性研究长脉冲1064nm Nd:YAG激光非侵入性治疗皮肤浅表静脉畸形的疗效。方法22例不同部位皮肤浅表静脉畸形患者接受长脉冲1064nm Nd:YAG激光治疗,6mm直径光斑,7～8ms双脉宽,脉冲间隔20ms,140～150J/cm2能量,接触式冷却,治疗间隔3周至1个月,治疗后1、6个月随访,评价病灶清除率分为五级。结果22例患者完成治疗,最多治疗5次。随访6个月,96.3%浅表静脉畸形获得76%～100%的清除,37%获得病灶的完全清除,未见复发。治疗部位无一例发生紫癜,治疗后8例(38.1%)出现红斑,1d至1个月消退。无色素改变和形成。结论长脉冲1064nm Nd:YAG激光能有效安全地治疗皮肤浅表静脉畸形,选择性地清除浅表血管,并使用接触冷却系统保护表皮,减少紫癜发生及色素改变和瘢痕的形成,达到理想的美容效果。     

术前无创正压通气治疗对脊柱侧凸患者围手术期肺功能的影响

目的:研究术前使用呼吸机无创正压通气治疗对脊柱侧凸患者围手术期肺功能的影响。方法:将40例Cobb角≥60°、肺功能存在中度以上限制性通气功能障碍、行脊柱侧凸矫形术的脊柱侧凸患者,随机分成A组和B组,每组20例。A组在术前采用BiPAP呼吸机,经用面罩无创正压通气(NIPPV)治疗1个月;B组常规术前准备。观察A组患者治疗前后肺功能的改善及两组患者围手术期肺功能的差异。结果:两组患者性别、年龄、身高、体重、Cobb角度、手术时间、手术径路、融合椎体数等基本情况比较无统计学差异(P>0.05);A组患者经NIPPV治疗后肺活量(VC)、肺活量占预计值的百分比(VC%)、用力肺活量(FVC)、第一秒最大呼气量(FEV1.0)、最大通气量(MVV)和最大通气量占预计值的百分比(MVV%)较治疗前明显改善(P<0.01);两组患者术中氧合指数、术后拔管时间、拔管后15min动脉血气PO2、PCO2比较有显著性差异(P<0.05)。结论:术前无创正压通气治疗可改善脊柱侧凸患者围手术期的肺功能,可缩短手术后气管插管的拔管时间,改善术后通气功能,有助于脊柱侧凸患者手术后早期恢复。     

介入法和无创法评价急性心肌梗死溶栓后心肌再灌注的一致性研究

目的 探讨急性心肌梗死（AMI）溶栓治疗后无创法评价心肌再灌注的可行性。方法选择AMI溶栓治疗后行冠状动脉造影的患者，溶栓后90min血浆肌红蛋白（Mb）浓度与溶栓前血浆Mb浓度比值≥2．4或心电图ST段回落≥50％定义为成功再灌注（阳性）。上述两项指标均阳性为完全再灌注，仅一项阳性为部分再灌注，两项均阴性为无再灌注。再根据冠状动脉造影结果将患者分为完全再灌注（TIMI3级）、部分再灌注（TIMI2级）、无再灌注（TIMI0～1级）。对无创法和介入法进行一致性检验。共入选45例患者。结果无创法和介入法评价心肌再灌注经一致性检验，符合率为84．4％，Kappa=0．75（P〈0．01）。结论．心电图ST段回落和血浆Mb浓度变化两项指标合用可提高评价心肌再灌注准确性，和介入法有很高的符合率，简便易行，且结果可靠。